放射性藥物市場規模、佔有率、成長分析，按類型、按適應症、按系統、按應用、按最終用戶、按地區 - 行業預測 2024-2031

2022年全球放射性藥物市場規模為65.2億美元，從2023年的67.4億美元成長到2031年的88.1億美元，預測期間（2024-2031年）預計複合年成長率為3.4%。

PET（正子斷層掃描）和 SPECT（單光子發射電腦斷層掃描）等診斷影像技術的進步徹底改變了醫療保健領域。這些創新顯著提高了診斷慢性疾病的特異性和敏感性，從而實現更快、更準確的診斷。一個值得注意的例子是，2023 年 6 月，GE Healthcare 推出了首款臨床實驗PET 核子醫學影像產品，旨在檢測和預測癌症免疫療法的反應。癌症、阿茲海默症和心臟病等慢性疾病的盛行率不斷上升，支持了對這些先進診斷工具不斷成長的需求。美國癌症協會預測，到2024年，美國將新增約299,000例前列腺癌病例，每年有八分之一的男性被診斷出來。此外，根據阿茲海默症協會的資料，目前約有 690 萬 65 歲以上的美國人患有阿茲海默症，預計到 2060 年這一數字將增加至 1,380 萬。慢性病的快速成長不僅凸顯了診斷影像技術在診斷和治療中的重要作用，也為醫療保健產業的相關人員帶來了巨大的市場成長機會。隨著對精確診斷解決方案的需求持續成長，投資創新成像技術可能會在不斷發展的醫療保健市場中產生豐厚的回報。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 專利分析
• 監管環境
• 技術景觀
• PESTEL分析
• 價值鏈分析
• 供應鏈分析

放射性藥物市場：依類型

• 市場概況
• 氟18衍生物
  • 氟18氟脫氧葡萄糖（FDG）
  • 氟18氟化鈉
  • 氟18氟昔考賓
  • 氟-18氟倍他吡
  • 氟-18氟苯甲酸酯
  • 其他
• Technetium99
• 鎦(Lu) 177
• 鎵68
  • DOTATATE
  • DOTATOC
• 鋯89
  • 11C-膽鹼
  • 14C-尿素
• 其他

放射性藥物市場：依適應症分類

• 市場概況
• 診斷
  • 神經病學
  • 神經退化性疾病（AD、PD 等）
  • 癲癇
• 心臟病學
• 其他

放射性藥物市場：依系統分類

• 市場概況
• PET
  • 獨立 PET 系統
  • 混合PET/CT
  • 混合PET/MRI
• SPECT

放射性藥物市場：依應用分類

• 市場概況
• 腫瘤學
• 心臟病學
• 胃腸病學
• 神經內分泌學
• 神經病學
• 腎臟病學
• 其他

放射性藥物市場：依最終用戶分類

• 市場概況
• 醫院
• 診斷實驗室
• 其他

放射性藥物市場：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Cardinal Health（US）
• Novartis Company（Switzerland）
• Lantheus（US）
• Curium（France）
• GE HealthCare（US）
• Jubilant Pharma Company（India）
• China Isotope & Radiation Corporation（China）
• Siemens Healthcare GmbH（Germany）
• Bracco（Italy）
• NTP（South Africa）
• Eckert & Ziegler（Germany）
• SHINE Technologies, LLC（US）
• EczacIbasI-Monrol（Turkey）
• IBA Worldwide（Belgium）
• Global Medical Solutions（US）
• BWX Technologies, Inc.（US）
• Institute of Isotopes（Hungary）
• Coqui Radiopharmaceuticals Corp.（US）
• Evergreen Theragnostics, Inc.（US）
• Isotope JSC（Russia）
• PharmaLogic Holdings Corp.（US）

Global Radiopharmaceuticals Market size was valued at USD 6.52 billion in 2022 and is poised to grow from USD 6.74 billion in 2023 to USD 8.81 billion by 2031, growing at a CAGR of 3.4% in the forecast period (2024-2031).

The healthcare landscape has been transformed by advances in imaging techniques like PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), which leverage radiopharmaceuticals to enhance the diagnostic capabilities of traditional imaging modalities, including CT and MRI. These innovations have significantly improved specificity and sensitivity in diagnosing chronic diseases, facilitating earlier and more accurate characterizations. A notable example is GE Healthcare's launch in June 2023 of the first investigational PET nuclear imaging product designed to detect and predict responses to cancer immunotherapies. The rising prevalence of chronic conditions such as cancer, Alzheimer's disease, and heart disease underscores the growing need for these advanced diagnostic tools. Projections from the American Cancer Society indicate that by 2024, there will be approximately 299,000 new prostate cancer cases in the U.S., with 1 in 8 men diagnosed annually. Moreover, data from the Alzheimer's Association reveals that approximately 6.9 million Americans aged 65 and older currently suffer from Alzheimer's disease, a figure expected to escalate to 13.8 million by 2060. This surge in chronic conditions not only highlights the critical role of enhanced imaging techniques in diagnosis and treatment but also signals significant market growth opportunities for stakeholders within the healthcare sector. As demand for precise diagnostic solutions continues to rise, investing in innovative imaging technologies is likely to yield substantial returns in the evolving healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiopharmaceuticals Market Segmental Analysis

Global Radiopharmaceuticals Market is segmented on the type, indication, system, application, end user, and region. By component, market is segmented into fluorine-18 derivatives, technetium-99, lutetium (Lu) 177, gallium-68, zirconium-89, and others. By indication, market is segmented into diagnosis, cardiology, and others. By system, market is segmented into PET, and SPECT. By Application, the market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others. By end user, market is segmented into Hospitals, Diagnostic Labs, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Radiopharmaceuticals Market

The escalating incidence of cancer globally is a significant market driver for the Global Radiopharmaceuticals market, as these specialized compounds play a crucial role in targeted and diagnostic oncology. With their ability to provide precise tumor localization and deliver therapeutic agents directly to malignant tissues, radiopharmaceuticals enhance treatment efficacy while minimizing adverse effects. This targeted approach not only improves patient outcomes but also aligns with the rising demand for personalized medicine, further fueling market growth. As healthcare systems increasingly prioritize advanced cancer therapies, the reliance on radiopharmaceuticals is expected to surge, propelling sustained investment and innovation in this sector.

Restraints in the Global Radiopharmaceuticals Market

The stringent regulatory framework governing the manufacture and approval of radiopharmaceuticals serves as a significant market restraint, hindering the growth potential of the sector. Compliance with rigorous safety and quality standards necessitates substantial investments in research, development, and manufacturing processes, often resulting in delayed product launches. The lengthy approval processes imposed by regulatory bodies further exacerbate these challenges, restricting market access for new therapeutic agents and imaging compounds. As manufacturers navigate the complexities of regulatory requirements, the resulting operational hurdles can deter investment and innovation, placing limitations on the overall expansion of the global radiopharmaceuticals market.

Market Trends of the Global Radiopharmaceuticals Market

The Global Radiopharmaceuticals market is witnessing a robust trend towards personalized medicine, driven by the increasing demand for targeted therapies that cater to individual patient profiles. This shift is particularly prominent in oncology and cardiology, where the ability to customize treatments based on specific genetic and disease characteristics enhances the efficacy of radiopharmaceuticals. As healthcare providers emphasize precision medicine, investments in research and development for innovative radiopharmaceuticals are on the rise. Consequently, this trend not only improves patient outcomes but also propels market growth, as stakeholders seek to harness the full potential of targeted therapies in clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Patent Analysis
• Regulatory Landscape
• Technological Landscape
• PESTEL Analysis
• Value Chain Analysis
• Supply Chain Analysis

Radiopharmaceuticals Market, By Type

• Market Overview
• Fluorine-18 Derivatives
  • Fluorine-18 Fludeoxyglucose (FDG)
  • Fluorine-18 Sodium Fluoride
  • Fluorine-18 Flucicovine
  • Fluorine-18 Florbetapir
  • Fluorine-18 Florbetaben
  • Others
• Technetium-99
• Lutetium (Lu) 177
• Gallium-68
  • Dotatate
  • Dotatoc
• Zirconium 89
  • 11C-choline
  • 14C-urea
• Others

Radiopharmaceuticals Market, By Indication

• Market Overview
• Diagnosis
  • Neurology
  • Neurodegenerative Disease (AD, PD, and Others)
  • Epilepsy
• Cardiology
• Others

Radiopharmaceuticals Market, By System

• Market Overview
• PET
  • Standalone PET systems
  • Hybrid PET/CT
  • Hybrid PET/MRI
• SPECT

Radiopharmaceuticals Market, By Application

• Market Overview
• Oncology
• Cardiology
• Gastroenterology
• Neuroendocrinology
• Neurology
• Nephrology
• Others

Radiopharmaceuticals Market, By End User

• Market Overview
• Hospitals
• Diagnostic Labs
• Others

Radiopharmaceuticals Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis Company (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharma Company (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Isotope & Radiation Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthcare GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NTP (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHINE Technologies, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EczacIbasI-Monrol (Turkey)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBA Worldwide (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Medical Solutions (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BWX Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institute of Isotopes (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coqui Radiopharmaceuticals Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Theragnostics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Isotope JSC (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharmaLogic Holdings Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments